Drug intelligence / Profile preview

gamma-aminobutyric acid + tramadol

Development stage
Approved
Lead developer
Physician Therapeutics
Modality
Small Molecules
Administration
Oral
01

Overview

A fixed-dose combination of **gamma-aminobutyric acid (GABA)**, a major inhibitory neurotransmitter in the central nervous system, and **tramadol**, a centrally acting synthetic opioid analgesic with serotonin-norepinephrine reuptake inhibition activity. This combination is formulated to provide enhanced pain relief; tramadol modulates pain via μ-opioid receptor agonism and inhibition of serotonin and norepinephrine reuptake, while gamma-aminobutyric acid may exert central inhibitory actions, though its pharmacological efficacy as a supplement is limited by blood-brain barrier permeability. The combo is usually indicated for moderate to severe pain where both neuropathic and nociceptive components are present, intending to produce synergistic analgesia through complementary action on multiple pain pathways[5][9].

02

Targets

SERT (Sodium-dependent serotonin transporter)ABAT (4-aminobutyrate aminotransferase)MOR (Mu opioid receptor)NMDAR (Glutamate receptor ionotropic, NMDA)NET (Norepinephrine Transporter)

Beyond the preview

Go deeper on gamma-aminobutyric acid + tramadol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gamma-aminobutyric acid + tramadol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call